Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee, subject to approval at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4886-20260302-02.pdf","jir_short_summary":"Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee, subject to approval at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.","jir_summary":"### Purpose of Transition to a Company with an Audit and Supervisory Committee\nAsuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee with the aim of enhancing management transparency and accelerating decision-making. The audit and supervisory committee will consist of a majority of outside directors, tasked with auditing and supervising the legality and appropriateness of business execution. Furthermore, decision-making authority regarding business execution by the board of directors will be delegated to the directors to promote prompt management decisions and execution.\n\n### Timing of the Transition and Future Plans\nThe transition to a company with an audit and supervisory committee is contingent upon the approval of amendments to the Articles of Incorporation at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026. Details regarding the amendments to the Articles of Incorporation and executive appointments will be announced once finalized.","jir_financial_highlights":"Scheduled Date of Transition to a Company with an Audit and Supervisory Committee: June 24, 2026 (New Transition)\nComposition of the Audit and Supervisory Committee: Majority of the members are outside directors (New Establishment)\nDelegation of Decision-Making Authority of the Board of Directors: Delegated to directors (New Implementation)","jir_category":"","jir_hashtags":"#AsukaPharmaceuticalHoldings, #GeneralIR, #CompanyWithAuditAndSupervisoryCommittee","jir_key_figures":"Scheduled Transition Date: June 24, 2026 (Date of the 5th Annual General Meeting of Shareholders)\nAudit and Supervisory Committee Composition: Majority of the members are outside directors\nDelegation of Board Authority: Decision-making authority regarding business execution delegated to directors","jir_meta_title":"Asuka Pharmaceutical Holdings Resolves to Transition to a Company with an Audit and Supervisory Committee in June 2026","jir_meta_description":"Asuka Pharmaceutical Holdings Co., Ltd. will transition to a company with an audit and supervisory committee upon approval at the shareholders meeting on June 24, 2026, aiming to enhance management transparency and accelerate decision-making.","jir_og_title":"Asuka Pharmaceutical Holdings Decides to Transition to a Company with an Audit and Supervisory Committee","jir_og_description":"Scheduled for approval at the shareholders meeting in June 2026. Establishing a system for enhanced management transparency and prompt decision-making.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-32582","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n